Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-analysis.
BACKGROUND
Resveratrol is a potential treatment option for management of non-alcoholic fatty liver disease (NAFLD) due to its anti-inflammatory, antioxidant properties, and calorie restriction-like effects. We aimed to synthesise evidence from published randomized clinical trials (RCTs) about the efficacy of resveratrol in the management of NAFLD.


METHODS
A computer literature search of PubMed, Scopus, Web of Science, and Cochrane Central was conducted using relevant keywords. Records were screened for eligible studies and data were extracted and synthesized using Review Manager Version 5.3 for windows. Subgroup analysis and sensitivity analysis were conducted.


RESULTS
Four RCTs (n=158 patients) were included in the final analysis. The overall effect estimates did not favor resveratrol group in terms of: serum ALT (MD -2.89, 95%CI [-15.66, 9.88], p=0.66), serum AST (MD -3.59, 95%CI [-13.82, 6.63], p=0.49), weight (MD -0.18, 95%CI [-0.92, 0.55], p=0.63), BMI (MD -0.10, 95 %CI [-0.43, 0.24], p=0.57), blood glucose level (MD -0.27, 95%CI [-0.55, 0.01], p=0.05), insulin level (MD -0.12, 95%CI [-0.69, 0.46], p=0.69), triglyceride level (MD 0.04, 95%CI [-0.45, 0.53], p=0.87), and LDL level (MD 0.21, 95%CI [-0.41, 0.83], p=0.51). Pooled studies were heterogeneous.


CONCLUSIONS
Current evidence is insufficient to support the efficacy of resveratrol in the management of NAFLD. Resveratrol does not attenuate the degree of liver fibrosis or show a significant decrease in any of its parameters.
Faculty of Medicine, Al Azhar University, Cairo, Egypt. Ahmedelgebaly94@azhar.edu.eg.
Ahmed
A
Elgebaly
Ain Shams University, Faculty of Medicine, Cairo University, Cairo, Egypt.
Ibrahim A I
IA
Radwan
Kasr-AlAiny Medical School, Cairo University, Cairo, Egypt.
Mohamed M
MM
AboElnas
Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
Hamza H
HH
Ibrahim
Genetic Engineering & Biotechnology Research Institute, University of Sadat City, Egypt.
Moutaz F M
MF
Eltoomy
Faculty of Veterinary Medicine, Cairo University, Cairo, Egypt.
Ahmed A
AA
Atta
Faculty of Medicine, Al Azhar University, Cairo, Egypt.
Hend A
HA
Mesalam
Faculty of Medicine, Beni Suef University,Beni Suef, Egypt.
Alaa A
AA
Sayed
Department of Pharmaceutics and Pharmaceutical Sciences, Faculty of Pharmacy, Alexandria University, Egypt.
Amr A
AA
Othman
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000975:Antioxidants / Q000627:therapeutic use*; D015982:Bias; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D016207:Cytokines / Q000097:blood; D006801:Humans; D008055:Lipids / Q000097:blood; D065626:Non-alcoholic Fatty Liver Disease / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D000077185:Resveratrol; D012720:Severity of Illness Index; D013267:Stilbenes / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000975:Antioxidants; D015415:Biomarkers; D001786:Blood Glucose; D016207:Cytokines; D008055:Lipids; D013267:Stilbenes; D000077185:Resveratrol